|
|
|
Clinical TrialsGastric CancerAdvanced or MetastaticTORI GI-04: A Phase II study to evaluate the efficacy and safety of Bevacizumab in combination with Capecitabine in frail patients with untreated metastatic gastric cancer. [UCLA] TORI GI-05: A Phase II study of Erlotinib (Tarceva) and modified FOLFOX 6 (5-Fluorocuracil, Leucovorin and Oxaliplatin) in previously untreated patients with unresectable or metastatic adenocarcinoma of the esophagus and gastric cardia. [UCLA]
For more information on VCHOS trials, please call Ruth Ann Begun at (805) 485-8709 ext 136 or email at rbegun@venturaoncology.com.For more information on UCLA network trials, please call Pamela Riach at (805) 485-8709 ext 129 or email at priach@mednet.ucla.edu.
|
|
Send mail to
webmaster@venturaoncology.com with
questions or comments about this web site.
|